Sponsored by Incyte Corporation
Join us for a live learning event in your area that is specifically designed to help patients take a closer look at the different types of myeloproliferative neoplasms (MPNs), a group of rare blood cancers. It is your chance to ask questions, meet with others who share your condition, and get support.
The speaker at this session will not provide medical advice. Your healthcare professional is the best source of information about your health.
Myeloproliferative neoplasms, or MPNs, are a group of rare blood cancers in which the body produces too many or too few mature blood cells. These diseases include:
Please Select a Location From Below:
Please complete and submit the registration form below
Please select the event location you would like to attend*
Call us: (919)-256-2472
Email us: firstname.lastname@example.org
†The meal offered at this program may be restricted and/or reported in accordance with state and federal law governing interactions with healthcare providers.
I understand that the personal information I provide on this Web site may be used by Incyte Corporation, or other companies acting on its behalf, to contact me via mail, via telephone, in electronic format, via Internet-based delivery, or otherwise in the future.
I authorize Incyte Corporation and its agents to contact me via mail, telephone, Internet-based or electronically (eg, Internet), or otherwise in the future and use and release information about me only for the purposes of (i) providing education and ongoing support services to me related to treatment, disease, and other areas of interest; and (ii) gathering feedback on my therapy treatment and/or disease state.
I understand that some of my information may be provided anonymously and used in an individual or aggregated form for other legitimate purposes by Incyte. Neither Incyte Corporation nor anyone working on behalf of Incyte will sell or rent personal information collected on this site.
I understand that I should check the Web site for the most recent version of Incyte Corporation's Legal Notices.